JSPR Insider Trading

Insider Ownership Percentage: 22.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $101,446.30

Jasper Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Jasper Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jasper Therapeutics Share Price & Price History

Current Price: $0.56
Price Change: Price Decrease of -0.0184 (-3.16%)
As of 12/7/2022 10:50 AM ET

This chart shows the closing price history over time for JSPR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Jasper Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/27/2022William LisDirectorSell24,743$2.08$51,465.4440,486View SEC Filing Icon  
6/24/2022William LisDirectorSell24,743$2.02$49,980.8665,229View SEC Filing Icon  
See Full Table
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
And It Could Spark An Economic Boom For Investors

SEC Filings (Institutional Ownership Changes) for Jasper Therapeutics (NASDAQ:JSPR)

71.83% of Jasper Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at JSPR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Jasper Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2022Vanguard Group Inc.530,120$0.42M0.0%+10.3%1.445%Search for SEC Filing on Google Icon
11/15/2022Citadel Advisors LLC3,102,016$2.45M0.0%+3.8%8.455%Search for SEC Filing on Google Icon
11/14/2022Forefront Analytics LLC119,800$94K0.1%+246.0%0.327%Search for SEC Filing on Google Icon
11/10/2022UBS Group AG188,026$0.15M0.0%+3,294.6%0.512%Search for SEC Filing on Google Icon
11/9/2022Fernwood Investment Management LLC297,080$0.23M0.1%N/A0.810%Search for SEC Filing on Google Icon
8/15/2022State Street Corp32,884$63K0.0%+51.2%0.087%Search for SEC Filing on Google Icon
5/16/2022Goldman Sachs Group Inc.10,451$37K0.0%-41.1%0.028%Search for SEC Filing on Google Icon
5/16/2022State Street Corp21,752$77K0.0%N/A0.057%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC10,871$39K0.0%N/A0.029%Search for SEC Filing on Google Icon
5/13/2022Federated Hermes Inc.251,697$0.89M0.0%-79.1%0.665%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.477,824$1.70M0.0%-1.2%1.262%Search for SEC Filing on Google Icon
5/10/2022Sectoral Asset Management Inc.675,000$2.40M0.4%N/A1.782%Search for SEC Filing on Google Icon
5/9/2022Forefront Analytics LLC32,550$0.12M0.0%N/A0.086%Search for SEC Filing on Google Icon
4/27/2022Vahanian & Associates Financial Planning Inc.10,000$36K0.1%-60.0%0.026%Search for SEC Filing on Google Icon
2/15/2022Kingdon Capital Management L.L.C.540,000$4.24M0.5%N/A1.427%Search for SEC Filing on Google Icon
2/2/2022Grace Capital218,110$1.71M1.0%N/A0.576%Search for SEC Filing on Google Icon
1/28/2022Vahanian & Associates Financial Planning Inc.25,000$0.20M0.2%N/A0.066%Search for SEC Filing on Google Icon
11/16/2021Citadel Advisors LLC3,005,035$29.22M0.0%N/A8.228%Search for SEC Filing on Google Icon
11/15/2021Tudor Investment Corp Et Al20,000$0.21M0.0%N/A0.055%Search for SEC Filing on Google Icon
11/15/2021Abingworth LLP5,628,558$58.03M13.2%N/A15.412%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Jasper Therapeutics logo
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Read More on Jasper Therapeutics

Today's Range

Now: $0.56
Low: $0.56
High: $0.56

50 Day Range

MA: $0.71
Low: $0.58
High: $0.89

52 Week Range

Now: $0.56
Low: $0.56
High: $10.69

Volume

45 shs

Average Volume

26,592 shs

Market Capitalization

$21.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Who are the company insiders with the largest holdings of Jasper Therapeutics?

Jasper Therapeutics' top insider investors include:
  1. William Lis (Director)
Learn More about top insider investors at Jasper Therapeutics.

Who are the major institutional investors of Jasper Therapeutics?

Jasper Therapeutics' top institutional shareholders include:
  1. Citadel Advisors LLC — 8.45%
  2. Vanguard Group Inc. — 1.45%
  3. Fernwood Investment Management LLC — 0.81%
  4. UBS Group AG — 0.51%
  5. Forefront Analytics LLC — 0.33%
Learn More about top institutional investors of Jasper Therapeutics stock.

Which institutional investors are buying Jasper Therapeutics stock?

In the previous quarter, JSPR stock was bought by institutional investors including:
  1. Fernwood Investment Management LLC
  2. UBS Group AG
  3. Citadel Advisors LLC
  4. Forefront Analytics LLC
  5. Vanguard Group Inc.
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
And It Could Spark An Economic Boom For Investors